These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinicopathologic study of fallopian tube closure after single transcervical insertion of quinacrine pellets.
    Author: Merchant RN, Prabhu SR, Kessel E.
    Journal: Int J Fertil Menopausal Stud; 1995; 40(1):47-54. PubMed ID: 7749435.
    Abstract:
    OBJECTIVE: To determine the effect on tubal closure of intrauterine quinacrine by dose and time from administration. DESIGN AND PARTICIPANTS: Subjects included 33 women of reproductive age who were awaiting hysterectomy for nonmalignant conditions at a Bombay, India medical college. Ten women received 252 mg quinacrine as pellets using a modified Copper-T IUD inserter followed by hysterectomy within 6 weeks, and 23 women received 324 mg quinacrine followed by hysterectomy 6 to 20 weeks post-insertion. Hysterosalpingograms were done before insertion, prior to surgery and on the fresh surgical specimen. The uteri and tubes were subjected to histology studies, including grading of tubal damage. For study of dose, an additional 7 women receiving 100 mg quinacrine (and previously reported) were included. MAIN OUTCOME MEASURE: Tubal closure rates by hysterosalpingogram and tubal histology. RESULTS AND CONCLUSION: Tubal closures were directly related to quinacrine dose and length of insertion-hysterectomy interval. For the 252 mg quinacrine dose, 55.0% of intramural tubal segments and 5.9% of isthmic segments showed histologic evidence of closure. For the 324 mg dose, all intramural tubal segments and 58.8% of isthmic segments showed histologic evidence of closure. Clinical conditions, such as dysfunctional uterine bleeding, were associated with lower tubal closure rates. Multivariate discriminant analysis showed quinacrine dose to be more important than quinacrine-hysterectomy interval. At B.Y.L. Nair Hospital in Bombay, India, physicians compared data on 10 women who had received 252 mg quinacrine in pellet form transcervically followed by a total hysterectomy within 6 weeks of quinacrine insertion with data on 23 women who had received 324 mg quinacrine in pellet form transcervically followed by a total hysterectomy 6-20 weeks after insertion. All the women were already scheduled for a hysterectomy for nonmalignant conditions. The researchers also included data on seven other women who had received 100 mg quinacrine earlier. They wanted to examine the effect on tubal occlusion of intrauterine quinacrine by dose and time. They conducted hysterosalpinograms before insertion, prior to hysterectomy, and on the fresh surgical specimens of the tubes and uterus. Women receiving the 324 mg dose had a much higher tubal closure rate than those receiving a 252 mg dose (100% vs. 50%; p = 0.01). With the 325 mg dose, all intramural tubal segments and 58.8% of isthmic segments had histologic stage II or III closure. With the 252 mg dose, 55% of intramural tubal segments and 5.9% of isthmic segments had stage III closure. A quinacrine-hysterectomy interval of at least seven weeks resulted in a better tubal closure rate than that of less than seven weeks (22/24 vs. 9/16; p = 0.01). Clinical conditions (pooled data; myomas, dysfunctional uterine bleeding, cervical intraepithelial neoplasia, and prolapse) were positively associated with tubal closure (31/40 vs. 9/40; p = 0.02). Quinacrine dose had a more significant effect on tubal closure than quinacrine-hysterectomy interval (standard discriminant function coefficient, 0.55 vs. 0.35).
    [Abstract] [Full Text] [Related] [New Search]